Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

209.46
-2.2750-1.07%
Post-market: 209.500.0400+0.02%19:50 EDT
Volume:2.12M
Turnover:444.42M
Market Cap:44.89B
PE:-23.48
High:212.74
Open:212.06
Low:206.75
Close:211.74
52wk High:220.34
52wk Low:35.62
Shares:214.34M
Float Shares:184.00M
Volume Ratio:1.37
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:17.23
PE(LYR):-35.20

Loading ...

Oppenheimer Adjusts Revolution Medicines PT to $195 From $165, Maintains Outperform Rating

MT Newswires Live
·
Jun 01

Revolution Medicines, Inc. : Oppenheimer Raises Target Price to $195 From $165

THOMSON REUTERS
·
Jun 01

Wedbush Reaffirms Their Buy Rating on Revolution Medicines (RVMD)

TIPRANKS
·
Jun 01

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 01

Oppenheimer Remains a Buy on Revolution Medicines (RVMD)

TIPRANKS
·
Jun 01

Summit drops as concerns over older patients cloud cancer trial data

Reuters
·
Jun 01

BUZZ-U.S. STOCKS ON THE MOVE -Revolution Medicines, FedEx, Xpeng

Reuters
·
Jun 01

MORNING BID AMERICAS-AI and 1984

Reuters
·
Jun 01

Revolution Medicines Pancreatic Cancer Trial Results Look Solid -- Market Talk

Dow Jones
·
Jun 01

Bellevue flags Merck-Kelun Sac-TMT Phase III OptiTROP-Lung05 data as top ASCO 2026 lung cancer catalyst

Reuters
·
Jun 01

Why doctors stood up and cheered mid-presentation for a historic pancreatic cancer treatment

Dow Jones
·
Jun 01

Stock Track | Revolution Medicines Soars 16.21% in Pre-Market on Breakthrough Pancreatic Cancer Trial Results

Stock Track
·
Jun 01

Movement Alert|Revolution Medicines Rises 15.38% in Pre-Market Trading, ASCO Phase 3 Pancreatic Cancer Data Far Exceeds Expectations

Market Focus
·
Jun 01

Stock Track | Revolution Medicines Soars 17.76% in Night Session on Positive Phase 3 Pancreatic Cancer Trial Results

Stock Track
·
Jun 01

Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs

Benzinga
·
Jun 01

Michael Yee Reiterates Buy Rating and Raises Price Target to $175 on Strong Pivotal Data and Launch Prospects for Daraxonrasib in Pancreatic Cancer

TIPRANKS
·
Jun 01

Movement Alert|Revolution Medicines Rises 7.95% Overnight, ASCO Conference RAS Inhibitor Pancreatic Cancer Data Fuels Market Optimism

Market Focus
·
Jun 01

Revolution Medicines announces results from Phase 3 RASolute 302 trial

TIPRANKS
·
Jun 01

Revolution Medicines Announces Asco Plenary Presentation Highlighting Unprecedented Results From Pivotal Phase 3 Rasolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

THOMSON REUTERS
·
May 31

CORRECTED-Revolution's pancreatic cancer drug doubles survival, boosts quality of life

Reuters
·
May 31